<?xml version='1.0' encoding='UTF-8'?>
<rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" version="2.0"><channel><title>Immunology</title><link>https://nrouizem.github.io/test/immunology_feed.xml</link><description>Daily curated &amp; summarized biopharma news.</description><atom:link href="https://nrouizem.github.io/test/immunology_feed.xml" rel="self"/><docs>http://www.rssboard.org/rss-specification</docs><generator>python-feedgen</generator><language>en</language><lastBuildDate>Thu, 13 Mar 2025 02:01:35 +0000</lastBuildDate><item><title>How 3T Biosciences’ platform targets immunologically cold solid tumors</title><link>https://www.drugdiscoverytrends.com/3t-biosciences-targeted-strategy-for-mss-colorectal-cancer/</link><description>3T Biosciences is developing a novel platform aimed at targeting immunologically cold solid tumors, addressing the challenge of immunotherapy resistance seen in conditions like microsatellite stable colorectal cancer. Over 90% of MSS CRC cases do not respond to existing checkpoint inhibitors, highlighting the urgent need for innovative therapeutic approaches in oncology.</description><pubDate>Sat, 01 Feb 2025 05:12:51 +0000</pubDate></item><item><title>Avoiding aggregates: How new technology is helping mAb developers monitor a vital CQA</title><link>https://www.drugdiscoverytrends.com/avoiding-aggregates-how-new-technology-is-helping-mab-developers-monitor-a-vital-cqa/</link><description>The market for monoclonal antibodies (mAbs) is projected to exceed $660 billion by 2030, driven by a growing research pipeline and escalating demand. To navigate challenges in maintaining critical quality attributes (CQAs), developers are leveraging new technologies that focus on effectively monitoring these vital requirements.</description><pubDate>Sat, 08 Feb 2025 19:54:03 +0000</pubDate></item><item><title>Rosnilimab phase 2b trial shows promise in treating RA</title><link>https://www.drugdiscoverytrends.com/rosnilimab-phase-2b-trial-shows-promise-in-treating-ra/</link><description>Rosnilimab has shown promising results in a phase 2b trial for treating rheumatoid arthritis (RA) by targeting the PD-1 pathway to reset the immune system and offer potential long-term remission for patients. This novel approach could provide a groundbreaking alternative to traditional therapies like methotrexate and biologics, which often fail to deliver sustained relief.</description><pubDate>Wed, 19 Feb 2025 14:07:47 +0000</pubDate></item><item><title>Solutions for CAR-Engineered Cell Characterization</title><link>https://www.fiercebiotech.com/resource/solutions-car-engineered-cell-characterization</link><description>Cell Signaling Technology (CST) has unveiled purpose-built tools, including recombinant antibodies targeting scFv linkers like G4S and Whitlow/218, to accelerate CAR-engineered cell characterization and development. The solutions aim to bypass the costly, time-intensive process of anti-idiotype antibody creation while streamlining workflows for researchers.</description><pubDate>Wed, 26 Feb 2025 14:49:25 +0000</pubDate></item><item><title>What FDA, NIH hearings say about Trump drug, health policy</title><link>https://endpts.com/what-fda-nih-hearings-say-about-trump-drug-health-policy/</link><description>President Trump's nominees for NIH director and FDA commissioner faced little opposition in their confirmation hearings, avoiding contentious discussions while offering broadly cautious responses. However, subtle hints about their policy views raised questions about potential future shifts in health agency priorities.</description><pubDate>Fri, 07 Mar 2025 17:45:21 +0000</pubDate></item><item><title>Multi-Modality Testing of EGFR</title><link>https://www.fiercebiotech.com/resource/multi-modality-testing-egfr</link><description>Neogenomics highlights its new white paper advocating a multi-modality testing approach to improve clinical trials, offering deeper insights into patient responses and treatment effectiveness. The sponsored resource, available for download, underscores how integrating diverse testing methods can advance oncology research and therapeutic outcomes.</description><pubDate>Fri, 07 Mar 2025 18:04:58 +0000</pubDate></item><item><title>Arrowhead reveals small batch of open-label data for 'non-core' kidney drug</title><link>https://endpts.com/arrowhead-reveals-small-batch-of-open-label-data-for-non-core-kidney-drug/</link><description>Arrowhead Pharmaceuticals unveiled promising new open-label data from its ARO-C3 RNAi therapy program, showing potential to improve kidney disease outcomes by targeting complement pathways in a small study involving about a dozen patients. The early-stage results highlight the therapy's novel approach to addressing kidney disorders, though no partnerships or business deals related to the program were disclosed.</description><pubDate>Mon, 10 Mar 2025 15:07:58 +0000</pubDate></item><item><title>J&amp;J, Protagonist outline first IBD win for potential immunological blockbuster</title><link>https://endpts.com/jj-protagonist-outline-first-ibd-win-for-potential-immunological-blockbuster/</link><description>Johnson &amp; Johnson and Protagonist Therapeutics have partnered to develop an oral IL-23 drug, aiming to create a breakthrough immunology treatment. The companies announced progress toward this goal on Monday, signaling potential advancements in bringing the blockbuster drug candidate closer to market.</description><pubDate>Mon, 10 Mar 2025 16:04:34 +0000</pubDate></item><item><title>The true cost of steroid-toxicity</title><link>https://www.drugdiscoverytrends.com/the-true-cost-of-steroid-toxicity/</link><description>Glucocorticoids, commonly known as steroids, are the standard treatment for autoimmune disorders due to their effectiveness in suppressing inflammation and alleviating symptoms. However, the article highlights the hidden costs of steroid toxicity, raising concerns over long-term health implications associated with their use.</description><pubDate>Tue, 11 Mar 2025 01:33:58 +0000</pubDate></item><item><title>MSD expands vaccine production with new $1bn facility</title><link>https://www.pharmaceutical-technology.com/news/msd-new-1bn-facility/</link><description>MSD has inaugurated a $1 billion facility in Durham, North Carolina, aimed at enhancing its vaccine manufacturing capacity. This significant investment underscores the company's commitment to expanding its production capabilities in response to growing global health demands.</description><pubDate>Tue, 11 Mar 2025 14:04:51 +0000</pubDate></item><item><title>Corrected: Merck opens billion-dollar US facility to make Gardasil</title><link>https://endpts.com/merck-opens-billion-dollar-facility-to-make-bladder-cancer-immunotherapy/</link><description>Merck has launched a new North Carolina-based manufacturing facility to produce HPV vaccines, including Gardasil and Gardasil 9, to meet rising global demand for cervical cancer prevention. The plant’s opening aligns with Merck’s strategy to expand production capacity amid increasing vaccine rollout efforts worldwide.</description><pubDate>Tue, 11 Mar 2025 14:50:06 +0000</pubDate></item><item><title>How technology advances are helping scientists unlock the mysteries of zoonotic diseases</title><link>https://www.drugdiscoverytrends.com/how-technology-advances-are-helping-scientists-unlock-the-mysteries-of-zoonotic-diseases/</link><description>In 2024, the World Health Organization expanded its pandemic watchlist by adding 24 pathogens, including three zoonotic diseases: avian influenza, mpox (formerly monkeypox), and the Sin Nombre virus, which has a 30% fatality rate. This move highlights the ongoing concern over diseases that can transfer from animals to humans and emphasizes the need for advancements in technology to better understand these threats.</description><pubDate>Tue, 11 Mar 2025 17:27:25 +0000</pubDate></item></channel></rss>